| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NUTLEY, N.J.—Continuing its expansion in the RNAi marketplace, Roche Holdings announced it entered into an R&D alliance with Alnylam Pharmaceuticals, covering four therapeutic areas initially: oncology, respiratory disease, metabolic disease, and specific liver diseases. The alliance will also see Roche acquire Alnylam's Kulmbach, Germany research site, which it will turn into a center of excellence for RNAi therapeutics discovery. The deal could be worth $1 billion.
 
"We look forward to working together to advance our transformative technology into a whole new class of drugs," said Dr. John Maraganore, Alnylam president and CEO. "Such significant support from Roche will also strengthen Alnylam's efforts to build a leading innovation-based biopharmaceutical company."
 
In exchange for a non-exclusive license to a range of RNAi-related IP, Alnylam will receive $331 million upfront in cash payments and a 5% equity investment, as well as the standard milestone payments and royalties on sales of commercialized products. Alnylam also retains the rights to non-exclusively license the IP to additional partners in other agreements.
 
Also as a result of the deal, Alnylam will pay Isis Pharmaceuticals $26.5 million in upfront fees and equity premium as part of a strategic alliance the two companies signed in 2004. "Working together we have made significant advances in RNAi technology and in creating drugs from this technology platform," says Isis chair and CEO Dr. Stan Crooke. "Isis has benefited substantially from Alnylam's business development and financial successes. We look forward to additional successes from this valuable strategic relationship."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue